Additionally, p-AKT was decreased when NFV was combined with doxorubicin in doxorubicin-resistant chronic myeloid leukemia cells [84] and with the proteasome inhibitor BZ in multiple myeloma cells [74]. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.